CD146: a potential therapeutic target for systemic sclerosis.
10.1007/s13238-018-0531-x
- Author:
Lingling ZHANG
1
;
Yongting LUO
2
;
Xiao TENG
3
;
Zhenzhen WU
4
;
Mengtao LI
1
;
Dong XU
1
;
Qian WANG
1
;
Fei WANG
4
;
Jing FENG
5
;
Xiaofeng ZENG
6
;
Xiyun YAN
7
Author Information
1. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China.
2. Beijing Advanced Innovation Center for Food Nutrition and Human Health, China Agricultural University, Beijing, 100193, China.
3. State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100037, China.
4. Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.
5. Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. fengjing@ibp.ac.cn.
6. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China. zengxfpumc@163.com.
7. Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. yanxy@ibp.ac.cn.
- Publication Type:Letter
- MeSH:
CD146 Antigen;
immunology;
Fibroblasts;
immunology;
pathology;
Humans;
Scleroderma, Systemic;
drug therapy;
immunology;
pathology
- From:
Protein & Cell
2018;9(12):1050-1054
- CountryChina
- Language:English
